TruScreen Group Limited Analysis

Overview

TruScreen's development began in the late 1980s under the guidance of leading medical academics from Sydney University.

TruScreen offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and wellbeing of women around the world.

Professor Coppleson, an international leader in colposcopy and cervical cancer, sought to establish objective technology that could improve on the conventional Pap test, which has limitations in population based screening due to its subjective nature and its need of laboratory facilities and qualified personnel. Dr. Reid believed that it should be possible to distinguish between normal and abnormal tissue by measuring changes in physical properties, such as electrical potential.

After almost 15 years of intensive R&D, the TruScreen 'Opto Electrical' Technology for the detection of cancerous cells is now being made commercially available to global markets. As the TruScreen technology is at the forefront of the development of objective opto-electric tissue differentiation it enjoys significant patent protection which is of great interest throughout the globe.

Following the restructuring of the business, TruScreen Pty Ltd, a subsidiary company of TruScreen Group Ltd (NZ), was formed in October 2013 to hold all TruScreen assets, including IP, and to act as the operations heart of the TruScreen business. The board and executive team combine experience and commercial ideas and strategies which we believe are both essential to and sufficient for the success of TruScreen globally.

TruScreen is a compliance listing there will be no new shares issued upon listing.

TruScreen is expected to commence trading on the NZX Alternative Board on 12 November 2014.

Performance

The following information was extracted from TruScreen Group Limited's Full Year Results, released on 29 May 2026

TruScreen FY2026 Preliminary Results

Highlights include:

• Launch of 5-year programme to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam

• TruScreen re-enters the Indian market and appoints Renovate Biologicals Pvt Ltd to distribute its AI enabled TruScreen cervical cancer screening system in India

• Landmark publication of the multi year and multi province clinical trial by Germany’s BMC Cancer. Notable publications including Sichuan University clinical study, and the Guilin People’s Hospital study, confirm TruScreen’s superiority as a primary screening medical device, and a superior screening choice for pregnant women

• TruScreen submitted three proposals to UNITAID's Global Cervical Cancer Elimination Call to Action, covering 14 high burden countries and an addressable screening market of 1Bn women.

• Growing TruScreen’s distribution network with appointment of new distributors in South Africa and Uzbekistan, with pending appointments in Nigeria, Romania, Bangladesh and Sri Lanka

Financial year 31 March 2026 was a year of marketing growth and consolidation for TruScreen.

Truscreen achieved product sales growth of 42% YOY to FY2026, and the sales were achieved from a broader range of participant countries. This included first sales in India with 468 million screening-age women and Indonesia with 95 million of screening age and a government funded mass screening program, creating enormous growth opportunity.